Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Exchanges Opinions with NPhA on Generics, Distribution
December 25, 2006
- Financial Support to Be Provided to Fewer Patients with Ulcerative Colitis, Parkinson's Disease
December 25, 2006
- JGPMA Proposes "Drug Benefit Standard Price System"
December 25, 2006
- MEDICAL DEVICE NEWS IN BRIEF
December 18, 2006
- NEW PRODUCTS
December 18, 2006
- NEW PRODUCTS
December 18, 2006
- REGULATORY NEWS IN BRIEF
December 18, 2006
- NIBIO Partnership Forum
December 18, 2006
- Tokai Univ. Symposium on Transfer of Technology
December 18, 2006
- Prime Minister Expresses High Hopes of Pharmaceutical Industry
December 18, 2006
- REGULATORY NEWS IN BRIEF
December 18, 2006
- Japanese Gov't Asks for Regular Meetings Between Japanese Companies and US FDA
December 18, 2006
- Institute Issues Proposals to Promote Regenerative Medicine
December 18, 2006
- Nichi-Iko Providing Third-party Data on Its Products
December 18, 2006
- US-Japan Gap in Approval Time Grew in 2005: OPIR
December 18, 2006
- ON THE MOVE
December 18, 2006
- Case Report on Problems with Generics Presented
December 18, 2006
- BUSINESS NEWS IN BRIEF
December 18, 2006
- Synix to Launch Improved Cancer Treatment Database
December 18, 2006
- ADVATE to Reach Japanese Hemophiliacs: Baxter
December 18, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…